Dermatitis News and Research

Latest Dermatitis News and Research

Invida announces launch of novel atopic dermatitis symptomatic treatment

Invida Group Private Limited reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair, which will be available to patients across Asia in second half of 2011.

26 May 2011

Gerber Products receives first qualified health claim from FDA for infant formulas

Today, Gerber Products Company, a part of the Nestlé family, announced that Gerber Good Start milk-based formulas are the first and only infant formulas that meet the criteria for a qualified health claim.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

New analytical method can improve detection of dimethyl fumarate in leather and footwear

Researchers at Igualada School of Engineering, a school associated with the Universitat Politècnica de Catalunya, have developed a new analytical method that improves detection of dimethyl fumarate in leather and footwear.

24 May 2011

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine's core technology.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Imaginary bugs flummox dermatologists

It is known that some people have the “delusional bug syndrome” and are convinced that bugs, worms, germs, or other creepy crawlers are infesting their skin and often see skin doctor after skin doctor to find out what is causing the infestation. Often, patients bring in samples of the insect and request a skin biopsy.

17 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

25 Apr 2011

Psoriasis patients still need long-established treatment alternatives

For patients with severe psoriasis, a new class of intravenous and injectable biological medicines known as "biologics" has brought about a near revolution in treatment.

21 Apr 2011

Normal routine use of topical corticosteroids for eczema in children does not 'thin the skin'

A new study published in the journal Pediatric Dermatology reveals that routine, long-term use of topical corticosteroids (TCS) for treating children with eczema does not cause any significant, negative side effects.

21 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011